Moderna’s Sales Miss Forecasts by 20%. Pfizer Is Taking the U.S. Vaccine Market.

3 years ago 398

Moderna shares plunged 12.3% successful premarket trading connected Thursday aft income of the company’s Covid-19 vaccine fell abbreviated of Wall Street analysts’ estimates by much than a cardinal dollars.

The institution reported full gross of $5 cardinal for the 3rd 4th of the year, 20% abbreviated of the FactSet expert statement estimation of $6.2 billion. Spikevax, Moderna‘s (ticker: MRNA) Covid-19 vaccine, is the company’s lone product.

The...

Read Entire Article

Moderna’s Sales Miss Forecasts by 20%. Pfizer Is Taking the U.S. Vaccine Market.

Related

How Achieve Content Syndication Success with Guest Posting

Top Pharmaceutical Stocks for Q1 2022

Cassava: An Attractive Value Proposition

Dow Jones Futures: Market Roars On This Fed Move; AMD, Nvidi...

Trending

Popular

What the Fed decision means for your wallet, your credit-car...

Taiwan Doctors Eye Blockchain to Track Covid-19 Vaccination

Polygon (MATIC) Price Rallies 11% Up to $1.19 – Where to Buy...

What is Apple Spatial Audio, how does it work and how to get...

Megan Fox and Machine Gun Kelly are engaged